Special Issue

Molecular Imaging for Cardiology: Radiopharmaceuticals for PET and SPECT

Message from the Guest Editors

Cardiovascular molecular imaging allows us to better understand the integrative biology and pathophysiology of diseases. It has become an essential part of daily clinical routine for both diagnosis and therapy monitoring: for example, myocardial perfusion scintigraphy is an integral part of the management of patients with known or suspected coronary heart disease. The advancements in the field are not limited to technical advances in computing and instrumentation but also include the use of established radiotracers for novel indications (e.g. 99mTc-labeled bone seeking agents for cardiac amyloidosis) as well as the development of perfusion radiotracers and targeted radiopharmaceuticals. Because of the tracer principle, these targeted probes have a high sensitivity and specificity for the target and allow to quantify the expression of a target or receptor occupancy and its changes during therapy. We cordially invite you to participate in this Special Issue, 'Molecular Imaging for Cardiology: Radiopharmaceuticals for PET and SPECT' with an original research article or review article.

Guest Editors

Dr. Olivier Gheysens

Department of Nuclear medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Dr. Hein J. Verberne

Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, location Academic Medical Center, Amsterdam, The Netherlands

Deadline for manuscript submissions

closed (31 March 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/84670

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

